New biotech Exalys, seek­ing to pre­vent post­op­er­a­tive delir­i­um, launch­es with $15 mil­lion in Se­ries A

An old group of for­mer col­leagues will be re­unit­ing to lead a new biotech ven­ture aimed at cul­ti­vat­ing a port­fo­lio to treat neu­roin­flam­ma­to­ry dis­or­ders. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER